Scarica l'app Stockscreener
7.71
17.89%
1.17
Precedente Chiudi:
$6.54
Aprire:
$6.47
Volume 24 ore:
164.33K
Relative Volume:
1.72
Capitalizzazione di mercato:
$48.71M
Reddito:
$28.83M
Utile/perdita netta:
$-13.34M
Rapporto P/E:
-5.0724
EPS:
-1.52
Flusso di cassa netto:
$-7.49M
1 W Prestazione:
+5.91%
1M Prestazione:
-7.33%
6M Prestazione:
-23.44%
1 anno Prestazione:
+399.03%
Intervallo 1D:
$6.47
$7.7199
Intervallo di 1 settimana:
$6.17
$7.7199
Portata 52W:
$1.44
$36.00
Exicure Inc Stock (XCUR) Company Profile
Nome
Exicure Inc
Settore
Industria
Telefono
847-673-1707
Indirizzo
2430 N. HALSTED ST., CHICAGO, IL
Confronta XCUR con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| 0.625 | 0 | 0 | 0 | 0 | 0.00 | |
GOODO
Gladstone Commercial Corporation
|
20.32 | 372.90M | 0 | 0 | 0 | 0.00 |
|
SHMD
Schmid Group N V
|
3.04 | 128.33M | 0 | 0 | 0 | 0.00 |
|
PSNYW
Polestar Automotive Holding Uk
|
0.1589 | 360.17M | 2.07B | -1.42B | -1.37B | -0.6765 |
|
DAVEW
Dave Inc
|
1.40 | 0 | 0 | 0 | 0 | 0.00 |
|
DWLD
Davis Select Worldwide ETF
|
41.60 | 0 | 0 | 0 | 0 | 0.00 |
Exicure Inc Stock (XCUR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2021-12-13 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2020-12-18 | Iniziato | BMO Capital Markets | Outperform |
| 2019-11-20 | Iniziato | Guggenheim | Buy |
Exicure Inc Borsa (XCUR) Ultime notizie
What makes Exicure Inc. stock price move sharplyStrategic High Profit Opportunities - Newser
Why Exicure Inc. stock attracts strong analyst attentionMarket Beating Strategy - Newser
Exicure Media Files Secondary Offering for Investors - MarketScreener
Exicure files for prospectus offering 5.2 mln common stock offered by selling stockholders - MarketScreener
How Exicure Inc. stock performs during market volatilityFree Wealth-Building Investment Strategies - beatles.ru
Exicure (NASDAQ:XCUR) Stock Price Up 2.3% – Should You Buy? - Defense World
When the Price of (XCUR) Talks, People Listen - news.stocktradersdaily.com
Exicure Plunges 11.36% Despite Russell Microcap Index Inclusion - AInvest
Exicure, Inc.(NasdaqCM: XCUR) added to Russell 3000E Index - MarketScreener
Exicure, Inc. Reports First Quarter 2025 Financial Results - BioSpace
Is Exicure, Inc. overvalued or undervalued? - MarketsMojo
Exicure (NASDAQ:XCUR) Stock Price Down 5.8% – Here’s Why - Defense World
Investors Can Still File Late Claims for Exicure $5.6M Settlement — Here’s How to Get Your Share - TradingView
What's Going On With Exicure Shares Monday? - MSN
Trading (XCUR) With Integrated Risk Controls - news.stocktradersdaily.com
XCURExicure, Inc. Reports Full Year 2024 Financial Results - mx.advfn.com
Exicure faces Nasdaq non-compliance notice By Investing.com - Investing.com South Africa
(XCUR) Trading Report - news.stocktradersdaily.com
Exicure Receives Nasdaq Delinquency Notification - TipRanks
Exicure faces Nasdaq non-compliance notice - Investing.com Australia
Exicure (XCUR) Faces Nasdaq Non-Compliance Due to Delayed Report - GuruFocus
Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-Q | XCUR Stock News - GuruFocus
Exicure Receives Noncompliance Notice From Nasdaq - marketscreener.com
Exicure (XCUR) Faces Nasdaq Non-Compliance Due to Delayed Report | XCUR Stock News - GuruFocus
Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-Q - Business Wire
Exicure (NASDAQ:XCUR) Trading Down 4.5% – Here’s Why - Defense World
Exicure (XCUR) Is Paying a $5.6M Settlement to Investors — Here’s How to Get Your Share - TradingView
Exicure Delays 10-Q Filing Amid Acquisition - TipRanks
(XCUR) Investment Analysis and Advice - news.stocktradersdaily.com
Exicure enters strategic convertible bond agreement By Investing.com - Investing.com Nigeria
Exicure Enters Convertible Bond Agreement with Subsidiary - TipRanks
Exicure enters strategic convertible bond agreement - Investing.com
Exicure concludes subject enrolment in trial of GPC-100 for multiple myeloma - Yahoo Finance
Exicure Completes Patient Enrollment in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant | XCUR Stock News - GuruFocus
Exicure Completes Patient Enrollment in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant - Business Wire
Geode Capital Management LLC Purchases Shares of 12,645 Exicure, Inc. (NASDAQ:XCUR) - Defense World
Exicure, Inc. (NASDAQ:XCUR) Sees Significant Drop in Short Interest - Defense World
Investors Can Still File Late Claims for Exicure $5.6M Settlement Payouts - TradingView
Why Exicure Inc. (XCUR) Soared on Monday - MSN
How To Trade (XCUR) - news.stocktradersdaily.com
10 Micro-, Small-Cap Companies Lead Monday’s Charge - Insider Monkey
Exicure, Inc. (NASDAQ:XCUR) Sees Large Drop in Short Interest - Defense World
Exicure Close to Finishing Patient Recruitment in Phase 2 Study of GPC-100 in Multiple Myeloma - MarketScreener
Exicure appoints new independent accounting firm By Investing.com - Investing.com India
Exicure, Inc. (Nasdaq: XCUR) Nears Completion of Phase 2 Study of GPC-100 in Multiple Myeloma - BioSpace
Exicure, Inc. (Nasdaq: XCUR) Nears Completion of Phase 2 Study o - GuruFocus
Exicure appoints new independent accounting firm - Investing.com Australia
Exicure, Inc. (Nasdaq: XCUR) Announces Their Next Step in Planning for a New Clinical Trial in Acute Myeloid Leukemia (AML) - BioSpace
Exicure Inc Azioni (XCUR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.64%
0.37%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):